Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Oncol Lett ; 7(6): 1829-1830, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24932241

RESUMEN

This report describes a dog with a clinical stage III oral malignant melanoma that was treated with complementary alternative medicine (CAM). The CAM included high temperature hyperthermia, dendritic cell therapy and lupeol injections. Surgery, radiation and chemotherapy were not performed. Two months after the start of treatment, the tumor disappeared and after six months, the follow-up examinations revealed no recurrence or metastasis of the tumor. Quality of life (QOL) of the dog was maintained; therefore, the application of CAM may be an effective treatment for canine oral malignant melanoma. The effective application of CAM has the potential to prolong life and maintain an excellent QOL for pets.

2.
J Vet Sci ; 15(1): 117-23, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24136207

RESUMEN

Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six felines) were treated with a novel triple therapy that combined photodynamic therapy, hyperthermia using indocyanine green with a broadband light source, and local chemotherapy after surgical tumor resection. This triple therapy was called photodynamic hyperthermal chemotherapy (PHCT). In all cases, the surgical margin was insufficient. In one feline case, PHCT was performed without surgical resection. PHCT was performed over an interval of 1 to 2 weeks and was repeated three to 21 times. No severe side effects, including severe skin burns, necrosis, or skin suture rupture, were observed in any of the animals. No disease recurrence was observed in seven out of 10 (70.0%) dogs and three out of six (50.0%) cats over the follow-up periods ranging from 238 to 1901 days. These results suggest that PHCT decreases the risk of STS recurrence. PHCT should therefore be considered an adjuvant therapy for treating companion animals with STS in veterinary medicine.


Asunto(s)
Antineoplásicos/uso terapéutico , Enfermedades de los Gatos/terapia , Enfermedades de los Perros/terapia , Verde de Indocianina/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Sarcoma/veterinaria , Animales , Enfermedades de los Gatos/tratamiento farmacológico , Enfermedades de los Gatos/cirugía , Gatos , Terapia Combinada/veterinaria , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/cirugía , Perros , Hipertermia Inducida/veterinaria , Fotoquimioterapia/veterinaria , Sarcoma/tratamiento farmacológico , Sarcoma/cirugía , Sarcoma/terapia
3.
Inflammation ; 35(4): 1462-5, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22434264

RESUMEN

We examined effects of N-acetyl-D: -glucosamine (GlcNAc) on rheumatoid arthritis (RA) mouse models and effects of GlcNAc and glucosamine hydrochloride (GlcN) on several serum cytokine productions in RA mouse models. SKG/jcl mice were divided into control, GlcNAc, and GlcN groups. For 56 days, the control group received normal food, the GlcNAc group received 0.5 % GlcNAc-containing food, and the GlcN group received 0.5 % GlcN-containing food. GlcNAc and GlcN equally suppressed arthritis scores and histopathological scores compared to the control group. In the GlcN group, serum tumor necrosis factor-α and interleukin (IL)-6 concentrations were significantly decreased compared to the control group. In the GlcNAc group, serum IL-10, transforming growth factor ß-1, and IL-2 concentrations were significantly increased compared to the control group. Our results indicated that GlcNAc also has suppressive effects on experimental RA in mouse models. The results of serum cytokine concentrations suggested that compared to GlcN, GlcNAc has a different suppressive mechanism in experimental RA models.


Asunto(s)
Acetilglucosamina/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Animales , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/inmunología , Artritis Experimental/metabolismo , Artritis Experimental/patología , Artritis Reumatoide/inmunología , Artritis Reumatoide/metabolismo , Artritis Reumatoide/patología , Modelos Animales de Enfermedad , Femenino , Glucosamina/uso terapéutico , Interleucina-10/sangre , Interleucina-2/sangre , Interleucina-6/sangre , Articulaciones/patología , Ratones , Factor de Crecimiento Transformador beta/sangre , Factor de Necrosis Tumoral alfa/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA